Medindia

X

VIVUS To Present at Deutsche Bank 35th Annual Healthcare Conference

Thursday, April 29, 2010 General News J E 4
Advertisement


MOUNTAIN VIEW, Calif., April 29 VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Deutsche Bank 35th Annual Healthcare Conference.

The VIVUS presentation will take place at the InterContinental Boston in Boston, Massachusetts on Wednesday, May 5, 2010 at 9:20 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of erectile dysfunction, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

CONTACT: -------- VIVUS, Inc. Investor Relations: The Trout Group Timothy E. Morris Brian Korb Chief Financial Officer 646-378-2923 650-934-5200 Media Relations: Pure Communications, Inc. Dan Budwick 973-271-6085

SOURCE VIVUS, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
West Announces First Quarter 2010 Results
S
Mylan Reports Adjusted Diluted EPS of $0.36 for th...